Watson Pharma to launch anemia drug
The drug has been approved as a treatment for anemia in adults and children six years of age or older, undergoing chronic hemodialysis who are receiving supplemental epoetin
China-based IMPACT Therapeutics and Pharmanovia have entered an exclusive licensing deal worth up to €423.5m ($488.3m), giving Pharmanovia rights to manufacture, develop, and commercialise senaparib in 66 countries.